SCHEMBL1492252

SCHEMBL1492252

CCOC(=O)c1c(NC(=O)Cc2ccccc2)cc(Cl)n1-c1ccc(CC)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.50
MAPK9 P45984 1/20 0.50
MAPK10 P53779 1/20 0.50
MAPT P10636 3/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
POLB P06746 3/20 0.44
LMNA P02545 2/20 0.44
RECQL P46063 1/20 0.44
HPGD P15428 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
PDE4D Q08499 1/20 0.42
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10008612 0.94 MAPK8 (0.50) MAPK8MAPK9MAPK10MAPTNPSR1
SCHEMBL10008143 0.92 MAPK8 (0.48) MAPK8MAPK9MAPK10MAPTNPSR1
SCHEMBL10008013 0.91 MAPK8 (0.47) MAPK8MAPK9MAPK10MAPTNPSR1
SCHEMBL10007607 0.91 MAPK8 (0.50) MAPK8MAPK9MAPK10MAPTALDH1A1
SCHEMBL10008779 0.89 MAPK8 (0.46) MAPK8MAPK9MAPK10MAPTNPSR1
SCHEMBL10007664 0.86 USP2 (0.51) MAPK8MAPK9MAPK10MAPTNPSR1
SCHEMBL10007824 0.86 MAPK8 (0.48) MAPK8MAPK9MAPK10MAPTNPSR1
SCHEMBL10008065 0.86 MAPK8 (0.43) MAPK8MAPK9MAPK10MAPTNPSR1
SCHEMBL10008582 0.86 SMN1; SMN2 (0.48) MAPTALDH1A1GAAPOLBLMNA
SCHEMBL1492350 0.85 SMN1; SMN2 (0.43) MAPTNPSR1ALDH1A1GAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2475660-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GlaxoSmithKline LLC (US) 2012-07-18 EP disclosed
US-20120172333-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2012-07-05 US disclosed
US-20120172333-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2012-07-05 US disclosed
WO-2011029855-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2011-03-17 WO disclosed
WO-2011029855-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172333-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK PRKAB1, PRKAG1, PRKAB2 MAPK8 458/4885MAPK9 440/4885MAPK10 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.